OVID

Ovid Therapeutics Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth↓ 1/10
  • Momentum↑ 9/10
Ovid Therapeutics sales and earnings growth
OVID Growth
Low
  • Revenue Y/Y↑ 945.89%
  • EPS Y/Y↓ -8.70%
  • FCF Y/Y↑ 34.47%
Ovid Therapeutics gross and profit margin trends
OVID Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -549.60%
  • ROIC↓ -62.50%
Ovid Therapeutics net debt vs free cash flow
OVID Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Ovid Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗